Incoming and outgoing links Biologika in der Dermatologie
Back to articleIncoming links
- Baricitinib
- DMARD
- JAK-Inhibitoren
- Monoklonale Antikörper
- Pseudo-SLE-Syndrom
- Quantiferon-TB-Gold-Test
- Rituximab
- Ustekinumab
Outgoing links
- Adalimumab
- Unerwünschte Arzneimittelwirkungen der Haut
- Baricitinib
- Bimekizumab
- BRAF-Inhibitoren
- Brodalumab
- Certolizumab Pegol
- Ciclosporin A
- CTLA-4
- Cytokine-release syndrome
- Zytokine
- Dupilumab
- Efalizumab
- EGF-Rezeptor-Inhibitoren
- Etanercept
- Golimumab
- Guselkumab
- Hand-Fuß-Syndrom
- Imatinib
- Immun-Checkpoint-Inhibitoren
- Infliximab
- Ipilimumab
- Ixekizumab
- JAK-Inhibitoren
- MEK-Inhibitoren
- Neutrophile ekkrine Hidradenitis
- Nivolumab
- Omalizumab
- PASI
- Pembrolizumab
- Pseudo-SLE-Syndrom
- Psoriasis vulgaris
- Rituximab
- Secukinumab
- Plattenepithelkarzinom der Haut
- Sunitinib
- TNF-alpha-Antagonisten
- Tyrosinkinaseinhibitoren
- Tyrosinkinasen
- Ustekinumab
- Vismodegib